Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Refractory TdT-Positive Leukemia
Conditions: official terms
Conditions: Keywords
refractory TdT-positive leukemia, ALL, AML, blastic CML
Study Type
Study Phase
Phase 1/Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: Cordycepin plus Pentostatin
Type: Drug
Overall Status
This is a two-part, open-label, Phase I/II study in subjects with relapsed or refractory TdT-positive leukemia for which no standard therapies are expected to result in durable remission.
Detailed Description
In the first phase the Study Objectives are to:

- Define the maximally tolerated dose (MTD) and recommended dose (RD) for administration of cordycepin as a 1-hour IV infusion, administered 1 hour following administration of an IV bolus of pentostatin, in subjects with refractory TdT-positive leukemia;

- Determine plasma ADA levels prior to pentostatin infusion and at 60 and 120 minutes after administration of pentostatin;

- Determine the single and multiple dose pharmacokinetics (PK) of cordycepin given 1 hour after a fixed dose of pentostatin;

- Assess cordycepin pharmacodynamics by measurement of blast cell apoptosis from peripheral blood smears;

- Measure and quantitate any clinical responses in refractory TdT-positive leukemia patients following cordycepin/pentostatin administration.

In the second phase, the Study Objectives are to assess the safety, PK, and clinical outcomes of cordycepin in combination with pentostatin, at the RD, in a 20 subject cohort
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- TdT-positive leukemia (ALL, AML, or blastic CML) that has failed at least one standard treatment regimen and for which no standard therapies are expected to result in durable remission. Leukemia is minimally defined as at least 20% blast cells present in marrow or peripheral blood. TdT must be expressed in at least 20% of blast cells present and documented either immunologically or biochemically;

- Age ≥18 years;

- Must understand and voluntarily sign informed consent;

- Adequate non-hematologic organ system function, defined by:

- Creatinine ≤1.5 times the upper limit of normal (ULN) and/or creatinine clearance ≥60 mL/min

- AST and/or ALT ≤2.5 times upper limit of normal (ULN)

- Total bilirubin within institutional normal range

- Normal EKG and LVEF >40%, measured by EKG and MUGA scan, radionuclide ventriculogram, or echocardiogram

- Life expectancy >3 months;

- Performance status (PS) >70% Karnofsky or ECOG ≤2;

- Women of childbearing potential must have a negative serum pregnancy test within 7 days of starting study drug. A woman of child-bearing potential is a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses at any time in the preceding 24 consecutive months);

- Male or female of child-bearing potential must agree to use adequate contraceptive methods

Exclusion Criteria:

- Failure to meet inclusion criteria;

- Uncontrolled active infection;

- Extramedullary (CNS) disease;

- Serious concomitant medical illness, such as active infection, uncontrolled congestive heart failure, or uncontrolled diabetes or other metabolic disorder, or psychiatric illness;

- Pregnancy or lactation; females of child bearing potential must use adequate contraceptive methods;

- Less than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to 24 hours before the study is initiated;

- Less than 2 months following bone marrow or peripheral blood stem cell transplantation or treatment with donor lymphocyte infusion (DLI).
Brigham & Women's Hospital
Boston, Massachusetts, United States
Status: Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Status: Recruiting
Contact: Daniel J DeAngelo, MD, PhD. - 617-632-2645 -
Cancer Therapy Reasearch Center at UTHSCA
San Antonio, Texas, United States
Status: Recruiting
Contact: Swaminathan Padmanabhan, MD - 210-450-5094 -
Start Date
June 2008
Completion Date
December 2010
OncoVista, Inc.
OncoVista, Inc.
Record processing date processed this data on July 28, 2015 page